Home › Major Depressive Disorder › Illinois
Major Depressive Disorder clinical trials in Illinois
20 studies for Major Depressive Disorder are looking for participants at sites in Illinois.
Cities in Illinois
A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder
- Charter Research - Chicago, Chicago
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 1, 2026 · NCT07775300A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Chicago Research Center, Chicago
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Oct 1, 2026 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Northwestern University, Chicago
- Baber Research Group, Naperville
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT06559306A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD)
- Chicago Research Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07621237A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- Endeavor Health Evanston Hospital, Evanston
RecruitingPhase 3
Ages 12 to 17 · All sexes · Updated Sep 25, 2026 · NCT07227454A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
- Rush University, Chicago
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 25, 2026 · NCT06793397Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 24, 2026 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Naperville
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07105111A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Advanced Quality Medical Research, Orland Park
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 8, 2026 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Chicago
- Draig Clinical Site, Skokie
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 2, 2026 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- Rush University Medical Center, Chicago
Recruiting
Ages 22 to 70 · All sexes · Updated Aug 28, 2026 · NCT06423430A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Uptown Research Institute, Chicago
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Aug 10, 2026 · NCT07592689A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- EmVenio Research, Chicago
RecruitingPhase 2
Ages 18 to 64 · All sexes · Updated Jul 27, 2026 · NCT07115329Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Chicago
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 24, 2026 · NCT07484217A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Flourish Research - Great Lakes Clinical Trials /ID# 278201, Chicago
- Amr Conventions Research /ID# 277547, Warrenville
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jun 15, 2026 · NCT07276997Exercise Training for Managing Major Depressive Disorder in Multiple Sclerosis
- University of Illinois at Chicago, Chicago
Recruiting
Ages 18 to 64 · All sexes · Updated Jun 4, 2026 · NCT05051618A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- Pillar Clinical Research LLC, Chicago
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated May 11, 2026 · NCT06524830Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Chicago Medical Center, Chicago
RecruitingObservational study
Ages 18 to 40 · All sexes · Updated Mar 10, 2026 · NCT06740383Study of ALTO-300 in MDD
- Site 310, Chicago
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Jul 24, 2025 · NCT05922878A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Chicago
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated Jan 23, 2025 · NCT06223880From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.